1259 related articles for article (PubMed ID: 29174026)
21. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.
Raschi E; Piccinni C; Poluzzi E; Marchesini G; De Ponti F
Acta Diabetol; 2013 Aug; 50(4):569-77. PubMed ID: 22008948
[TBL] [Abstract][Full Text] [Related]
22. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
Ren X; Wang H; Deng L; Wang W; Wang Y
Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
[TBL] [Abstract][Full Text] [Related]
23. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
24. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
25. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
26. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
[TBL] [Abstract][Full Text] [Related]
27. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
Kong W; Mao W; Zhang L; Wu Y
Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
[TBL] [Abstract][Full Text] [Related]
28. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
Filippini DM; Gatti M; Di Martino V; Cavalieri S; Fusaroli M; Ardizzoni A; Raschi E; Licitra L
Int J Cancer; 2021 Aug; 149(3):675-683. PubMed ID: 33844854
[TBL] [Abstract][Full Text] [Related]
29. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
Battini V; Carnovale C; Clementi E; Sessa M
Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
[TBL] [Abstract][Full Text] [Related]
30. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
[TBL] [Abstract][Full Text] [Related]
31. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
Chai S; Zhan JL; Zhao LM; Liu XD
Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
[TBL] [Abstract][Full Text] [Related]
32. [Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database].
Esteban-Jiménez O; Navarro-Pemán C; Urieta-González L
Semergen; 2018; 44(1):23-29. PubMed ID: 29183654
[TBL] [Abstract][Full Text] [Related]
33. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
34. Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS.
Zhou X; Ye X; Guo X; Liu D; Xu J; Hu F; Zhai Y; Gao Y; Xu X; Dong Z; He J
Front Pharmacol; 2021; 12():766125. PubMed ID: 34987394
[No Abstract] [Full Text] [Related]
35. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.
Muhammed A; Thomas C; Kalaiselvan V; Undela K
Expert Opin Drug Saf; 2024 Jun; 23(6):731-742. PubMed ID: 37986140
[TBL] [Abstract][Full Text] [Related]
36. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
37. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
Alkabbani W; Gamble JM
Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
[TBL] [Abstract][Full Text] [Related]
38. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Fahim SM; Mishuk AU; Cheng N; Hansen R; Calderón AI; Qian J
Expert Opin Drug Saf; 2019 Feb; 18(2):145-152. PubMed ID: 30576263
[TBL] [Abstract][Full Text] [Related]
39. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis.
Gravel CA; Krewski D; Mattison DR; Momoli F; Douros A
Br J Clin Pharmacol; 2023 Aug; 89(8):2430-2445. PubMed ID: 36912450
[TBL] [Abstract][Full Text] [Related]
40. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
